BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 2145933)

  • 1. Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodgkin's lymphoma.
    Teske E; Rutteman GR; van Heerde P; Misdorp W
    Eur J Cancer; 1990; 26(8):891-5. PubMed ID: 2145933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase combined with chemotherapy. A randomized double-blind study in canine lymphoma.
    MacEwen EG; Rosenthal RC; Fox LE; Loar AS; Kurzman ID
    J Vet Intern Med; 1992; 6(4):230-4. PubMed ID: 1522554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preliminary study on the evaluation of asparaginase. Polyethylene glycol conjugate against canine malignant lymphoma.
    MacEwen EG; Rosenthal R; Matus R; Viau AT; Abuchowski A
    Cancer; 1987 Jun; 59(12):2011-5. PubMed ID: 3567863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma.
    Agrawal NR; Bukowski RM; Rybicki LA; Kurtzberg J; Cohen LJ; Hussein MA
    Cancer; 2003 Jul; 98(1):94-9. PubMed ID: 12833461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
    Ettinger LJ; Kurtzberg J; Voûte PA; Jürgens H; Halpern SL
    Cancer; 1995 Mar; 75(5):1176-81. PubMed ID: 7850718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma.
    Muss HB; Spell N; Scudiery D; Capizzi RL; Cooper MR; Cruz J; Jackson DV; Richards F; Spurr CL; White DR
    Invest New Drugs; 1990 Feb; 8(1):125-30. PubMed ID: 2345067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor enzyme: polyethylene glycol-modified asparaginase.
    Wada H; Imamura I; Sako M; Katagiri S; Tarui S; Nishimura H; Inada Y
    Ann N Y Acad Sci; 1990; 613():95-108. PubMed ID: 2076022
    [No Abstract]   [Full Text] [Related]  

  • 8. A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors.
    Taylor CW; Dorr RT; Fanta P; Hersh EM; Salmon SE
    Cancer Chemother Pharmacol; 2001; 47(1):83-8. PubMed ID: 11221967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of PEG-L-asparaginase in asparagine suppression and anti-drug antibody development in healthy Beagle dogs: A multi-phase preclinical study.
    Feenstra LR; Gehring R; van Geijswijk IM; König T; Prinsen HCMT; Vandemeulebroecke K; Lammens T; Krupa A; Teske E
    Vet J; 2022 Aug; 286():105854. PubMed ID: 35781075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient.
    Sahiner UM; Yavuz ST; Gökce M; Buyuktiryaki B; Altan I; Aytac S; Tuncer M; Tuncer A; Sackesen C
    Pediatr Int; 2013 Aug; 55(4):531-3. PubMed ID: 23910807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors for treatment of malignant lymphoma in dogs.
    Teske E; van Heerde P; Rutteman GR; Kurzman ID; Moore PF; MacEwen EG
    J Am Vet Med Assoc; 1994 Dec; 205(12):1722-8. PubMed ID: 7744644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols.
    Müller HJ; Beier R; da Palma JC; Lanvers C; Ahlke E; von Schütz V; Gunkel M; Horn A; Schrappe M; Henze G; Kranz K; Boos J
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):149-54. PubMed ID: 11862429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High efficacy of monomethoxypolyethylene glycol-conjugated L-asparaginase (PEG2-ASP) in two patients with hematological malignancies.
    Kawashima K; Takeshima H; Higashi Y; Hamaguchi M; Sugie H; Imamura I; Wada H
    Leuk Res; 1991; 15(6):525-30. PubMed ID: 1861535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol.
    Raja RA; Schmiegelow K; Albertsen BK; Prunsild K; Zeller B; Vaitkeviciene G; Abrahamsson J; Heyman M; Taskinen M; Harila-Saari A; Kanerva J; Frandsen TL;
    Br J Haematol; 2014 Apr; 165(1):126-33. PubMed ID: 24428625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-asparaginase for treatment of lymphoid neoplasia in dogs.
    Rogers KS
    J Am Vet Med Assoc; 1989 Jun; 194(11):1626-30. PubMed ID: 2568982
    [No Abstract]   [Full Text] [Related]  

  • 18. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
    Tram Henriksen L; Gottschalk Højfeldt S; Schmiegelow K; Frandsen TL; Skov Wehner P; Schrøder H; Klug Albertsen B;
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28660740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma ammonia concentration after L-asparaginase therapy in 27 dogs with high-grade lymphoma or leukemia.
    Speas AL; Lyles SE; Wirth KA; Fahey CE; Kow K; Lejeune AT; Milner RJ
    J Vet Emerg Crit Care (San Antonio); 2018 Mar; 28(2):130-139. PubMed ID: 29469204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma.
    Jeffreys AB; Knapp DW; Carlton WW; Thomas RM; Bonney PL; Degortari A; Lucroy MD
    J Am Anim Hosp Assoc; 2005; 41(4):221-6. PubMed ID: 15995158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.